{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:22:17Z","timestamp":1794579737948,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40121-018-0214-1","type":"journal-article","created":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T21:56:41Z","timestamp":1538344601000},"page":"439-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":434,"title":["Effect and Safety of Meropenem\u2013Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial"],"prefix":"10.1007","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct02168946","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Richard G.","family":"Wunderink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Rahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Mathers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Solomkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanaya","family":"Bhowmick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Bishara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Daikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Felton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose Lopez","family":"Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jeong","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Menichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lomovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Loutit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"214_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-017-4878","author":"M Bassetti","year":"2017","unstructured":"Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A. Antimicrobial resistance in the next 30\u00a0years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 2017. https:\/\/doi.org\/10.1007\/s00134-017-4878.","journal-title":"Intensive Care Med."},{"key":"214_CR2","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. https:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/index.html. Accessed 27 Aug 2017."},{"key":"214_CR3","unstructured":"World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. http:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic-resistant-bacteria\/en\/. Accessed 5 Sep 2017."},{"key":"214_CR4","unstructured":"European Commission. A European One Health action plan against antimicrobial resistance (AMR). https:\/\/ec.europa.eu\/health\/amr\/action_eu_en. Accessed 5 Sep 2017."},{"key":"214_CR5","unstructured":"The Pew Charitable Trusts. GAIN: how a new law is stimulating the development of antibiotics. http:\/\/www.pewtrusts.org\/en\/research-and-analysis\/issue-briefs\/2013\/11\/07\/gain-how-a-new-law-is-stimulating-the-development-of-antibiotics. Accessed 5 Sep 2017."},{"key":"214_CR6","volume-title":"Tackling drug-resistant infections globally: an overview of our work. The review on antimicrobial resistance","author":"J O\u2019Neill","year":"2016","unstructured":"O\u2019Neill J. Tackling drug-resistant infections globally: an overview of our work. The review on antimicrobial resistance. London: Wellcome Trust; 2016."},{"issue":"3","key":"214_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","volume":"8","author":"JD Pitout","year":"2008","unstructured":"Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159\u201366.","journal-title":"Lancet Infect Dis."},{"issue":"9","key":"214_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","volume":"13","author":"LS Munoz-Price","year":"2013","unstructured":"Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785\u201396.","journal-title":"Lancet Infect Dis."},{"key":"214_CR9","doi-asserted-by":"crossref","unstructured":"Giacobbe DR, Del Bono V, Trecarichi EM, et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Societ\u00e0 Italiana Terapia Antinfettiva). Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect. 2015;21(12):1106.e1\u20131106.e8.","DOI":"10.1016\/j.cmi.2015.08.001"},{"issue":"42","key":"214_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2807\/1560-7917.ES2014.19.42.20939","volume":"19","author":"M Monaco","year":"2014","unstructured":"Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill. 2014;19(42):14\u20138.","journal-title":"Euro Surveill"},{"key":"214_CR11","doi-asserted-by":"crossref","unstructured":"Shields RK, Chen L, Cheng S, et al Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61(3):3e02097-16-3e020916.","DOI":"10.1128\/AAC.02097-16"},{"issue":"2","key":"214_CR12","doi-asserted-by":"crossref","first-page":"ofx063","DOI":"10.1093\/ofid\/ofx063","volume":"4","author":"EL Alexander","year":"2017","unstructured":"Alexander EL, Loutit J, Tumbarello M, et al. Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Inf Dis. 2017;4(2):ofx063.","journal-title":"Open Forum Inf Dis."},{"issue":"2","key":"214_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1128\/AAC.01222-13","volume":"58","author":"ME Falagas","year":"2014","unstructured":"Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58(2):654\u201363.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"214_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/cid\/cis588","volume":"55","author":"M Tumbarello","year":"2012","unstructured":"Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943\u201350.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"214_CR15","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1128\/AAC.02166-13","volume":"58","author":"GL Daikos","year":"2014","unstructured":"Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"214_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/21505594.2016.1213472","volume":"8","author":"SM Pouch","year":"2017","unstructured":"Pouch SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence. 2017;8(4):391\u2013402.","journal-title":"Virulence."},{"issue":"9","key":"214_CR17","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","volume":"58","author":"SJ Hecker","year":"2015","unstructured":"Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs. class A serine carbapenemases. J Med Chem. 2015;58(9):3682\u201392.","journal-title":"J Med Chem"},{"key":"214_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02228-17","author":"CM Rubino","year":"2018","unstructured":"Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN, Griffith DC (2018) Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02228-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"214_CR19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem\u2013vaborbactam vs. piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788\u201399.","journal-title":"JAMA"},{"key":"214_CR20","unstructured":"FDA approves new antibacterial drug [press release]. Silver Spring, MD: US Food and Drug Administration; August 29, 2017. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm573955.htm. Accessed 3 Sep 2017."},{"issue":"10","key":"214_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818\u201329.","journal-title":"Crit Care Med"},{"key":"214_CR22","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne: Clinical and Laboratory Standards Institute; 2014."},{"key":"214_CR23","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Antimicrobial susceptibility testing. 2014. http:\/\/www.eucast.org\/ast_of_bacteria\/. Accessed 27 Aug 2017."},{"key":"214_CR24","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed 27 Aug 2017."},{"issue":"11","key":"214_CR25","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00134-001-1120-6","volume":"27","author":"R Bellomo","year":"2001","unstructured":"Bellomo R, Kellum J, Ronco C. Acute renal failure: time for consensus. Intensive Care Med. 2001;27(11):1685\u20138.","journal-title":"Intensive Care Med"},{"issue":"7","key":"214_CR26","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1093\/jac\/dkv086","volume":"70","author":"M Tumbarello","year":"2015","unstructured":"Tumbarello M, Trecarichi EM, De Rosa FG, et al. ISGRI-SITA (Italian Study Group on Resistant Infections of the Societ\u00e0 Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133\u201343.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"214_CR27","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1128\/AAC.00782-08","volume":"53","author":"GL Daikos","year":"2009","unstructured":"Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009;53(5):1868\u201373.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"214_CR28","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1073\/pnas.1616248114","volume":"114","author":"GC Cerqueira","year":"2017","unstructured":"Cerqueira GC, Earl AM, Ernst CM, et al. Multi-institute analysis of carbapenem resistance reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaks. Proc Natl Acad Sci USA. 2017;114(5):1135\u201340.","journal-title":"Proc Natl Acad Sci USA"},{"key":"214_CR29","doi-asserted-by":"crossref","unstructured":"Glasner C, Albiger B, Buist G, et al Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill. 2013;18(28):20525. http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=20525. Accessed 27 Aug 2017.","DOI":"10.2807\/1560-7917.ES2013.18.28.20525"},{"issue":"3","key":"214_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/0885066614555490","volume":"31","author":"SJ Lewis","year":"2014","unstructured":"Lewis SJ, Mueller BA. Antibiotic dosing in patients with acute kidney injury: \u2018enough but not too much\u2019. J Intensive Care Med. 2014;31(3):164\u201376.","journal-title":"J Intensive Care Med."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-018-0214-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-018-0214-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-018-0214-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:10:10Z","timestamp":1728907810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-018-0214-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["214"],"URL":"https:\/\/doi.org\/10.1007\/s40121-018-0214-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734137867.793560863","asserted-by":"object"}]},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]},"assertion":[{"value":"13 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}